Skip to main content
Figure 2 | BMC Infectious Diseases

Figure 2

From: Impact of antiviral treatment and hospital admission delay on risk of death associated with 2009 A/H1N1 pandemic influenza in Mexico

Figure 2

Temporal evolution of neuraminidase inhibitor administration rates and the case fatality ratio by date of symptoms onset during the 2009 A/H1N1 influenza pandemic in Mexico, AprilDecember 2009. A) Monthly number of new laboratory-confirmed A/H1N1 influenza outpatients and inpatients, B) Monthly percentage of laboratory-confirmed A/H1N1 influenza outpatients and A/H1N1 inpatients that received antiviral medications during the pandemic period, and C) the monthly case fatality ratio (and corresponding 95% CIs) based on all A/H1N1 influenza cases during the pandemic period.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us